CAR T Progress: Global Submissions for Kymriah, 42% Ongoing Response With Yescarta in ZUMA-1 Patients
Surabhi Dangi-Garimella, PhD
Coverage from the 59th Annual Meeting and Exposition of the American Society of Hematology, December 9-12, 2017.
A much-anticipated session on the second day of the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Atlanta, Georgia, provided long-term
updates on trials evaluating 2 chimeric antigen receptor (CAR) T-cell treatments: tisagenlecleucel, or CTL019 (Kymriah), for the treatment of adult relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), and axicabtagene ciloleucel (Yescarta), which was evaluated in patients with refractory aggressive non-Hodgkin lymphoma (NHL).
Tisagenlecleucel was the first CAR T-cell treatment to be approved in certain pediatric and young adult patients with B-cell precursor acute lymphoblastic leukemia. Results from
the single-arm, open-label, multicenter, global, pivotal phase 2 JULIET trial of CTL019 in adults with r/r DLBCL were presented by Stephen Schuster, MD, professor, Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania.1 Conducted in 27 study centers located in 10 countries around the world, the CAR T cells were manufactured in the United States and Germany.
The primary objective was met at the interim analysis, with the best overall response rate (ORR) of 59%, Schuster reminded the audience. His presentation provided results from the primary analysis of JULIET data, with the primary endpoint defined as best ORR (complete response [CR] + partial response [PR]) per independent review committee.
Eligibility criteria for JULIET included age 18 or older with r/r DLBCL, progression after receiving at least 2 lines of chemotherapy, and ineligible for or failed autologous stem cell transplant. Shuster shared a flow chart depicting the study status for JULIET, which had a data cutoff of March 8, 2017. Of the 147 patients who initially enrolled in the trial, 43 patients left the trial prior to infusion and 5 were pending infusion. Of the 99 who received a single CTL019 infusion, 81 were evaluable for response, 89 had received bridging chemotherapy, and 92 had received lymphodepleting chemotherapy (73% received fludarabine 25 mg/m2 and cyclophosphamide 250 mg/m2/day for 3 days; 19% received bendamustine 90 mg/m2/day for 2 days).
The best ORR in the 81 patients was 53%, with 40% achieving a CR and 14% achieving a PR. The 3-month ORR was 38% (32% CR + 6% PR) and ORR at 6 months was 37% (30% CR + 7% PR). “The durability off the CTL019 response is shown by the stability between the 3- and 6-month response rates,” Schuster pointed out, adding that the 3-month response hints at a more long-term benefit of this treatment.
Subgroup analysis also showed consistent ORR across the various cohorts:
“The median duration of response and median overall survival had not been reached at data cutoff,” Schuster said. He also indicated that 74% of patients were relapse free at 6
months and almost all patients who had a CR at 3 months remained relapse-free. “Patients who responded with either a CR or a PR did not proceed to receive allogenic- or auto-stem
cell transplant,” he added.
Overall, 86% of patients had grade 3 or 4 adverse events (AEs). Cytokine release syndrome (CRS) occurred in 58% of infused patients: 15% were grade 3 and 8% were grade 4. About 15% of patients received anti-IL6 therapy (tocilizumab) for CRS management, with good response, and 11% of patients received corticosteroids. Other grade 3 or 4 AEs included neurologic AEs (12%, managed with supportive care), cytopenias lasting longer than 28 days (27%), infections (20%), and febrile neutropenia (13%).
Three patients died within 30 days of infusion, all due to disease progression. No deaths were attributed to CTL019, CRS, or neurologic events.
Of the 26 (26%) patients in the study who received outpatient infusion, 20 (77%) remained on outpatient status for at least 3 days following infusion, “which means tisagenlecleucel can be safely administered in both the inpatient and the outpatient settings,” Schuster concluded.
Speaking during a press briefing in advance of the annual meeting, 2017 ASH President Kenneth C. Anderson, MD, highlighted the international scope of the JULIET trial, which he said indicates a much broader reach of this treatment.
The future plans for JULIET include:
• Ongoing global regulatory submissions
• Large-scale production of tisagenlecleucel
• A 22-day manufacturing time in the commercial setting
The second study was a 15.4-month follow-up on ZUMA-1, which is designed to evaluate axicabtagene ciloleucel (Axi-cel, Yescarta) in patients with refractory aggressive NHL.2 Axi-cel became the second approved CAR T-cell treatment, in October, for adult patients with DLBCL. The results were presented by Sattva S. Neelapu, MD, professor in the Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center.
The results were simultaneously published in the New England Journal of Medicine.3 The primary analysis of ZUMA-1 demonstrated positive results, Neelapu said, with an ORR of 82% and a CR rate of 54% after a single infusion of axicel. The treatment had a manageable safety profile as well: grade ≥3 CRS and neurologic events were generally reversible and reported in 13% and 28% of patients, respectively. “At a median follow-up of 8.7 months, 44% of patients in ZUMA-1 had an ongoing response,” Neelapu indicated.
The study population included patients with refractory DLBCL (n = 77), and transformed follicular lymphoma or primary mediastinal large B cell lymphoma (total n = 24). Patients were
treated with cyclophosphamide (500 mg/m2) plus fludarabine (30 mg/m2) for 3 days to condition the body prior to treatment with 2x106 CAR-positive T cells/kg.
“While the CAR T-cell product was successfully manufactured in 99% of enrolled patients, only 91% received the infusion,” Neelapu said. Eligibility criteria included:
• Refractory disease, defined as progressive disease or stable disease as best response to last line of therapy
• Relapse ≤12 months after autologous stem cell transplant
• Prior anti-CD20 antibody and an anthracycline-containing regimen
The primary endpoint was ORR and secondary endpoints included duration of response (DOR), overall survival (OS), and incidence of AEs. A key exploratory endpoint was to investigate the mechanisms of resistance using posttreatment tumor biopsies obtained at time of relapse or progression. “To date, no patients have been lost to follow-up,
and all patients who are alive remain in disease and survival follow-up,” Neelapu told the audience.
Following analysis of results from the trial, at a data cut-off date of August 11, 2017, which was a 15.4-month follow-up, the best ORR was 82%, with a CR rate of 58%. Neelapu noted that patients who had a PR at the first tumor assessment (which was 1 month post infusion) had a CR up to 15 months post infusion, without need for additional treatment. The median time for conversion from PR to CR was 64 days (range, 49-424).
Overall DOR was 11.1 months (range, 3.9-not reached), CR was not reached, and PR was 1.9 months (range, 1.4-2.1). “Forty-three percent of phase 1 patients have an ongoing CR
at 24 months,” he said. The following are the 15.4-month survival updates from the study:
• Median progression-free survival: 5.8 months (range, 3.2-not reached)
• Median OS: not reached (range, 12.0-not reached)
With respect to AEs, Neelapu said that 95% of patients had grade 3 or higher AEs (43% of which were serious adverse events [SAEs]) in the primary analysis, which increased to 97% in the updated analysis (46% SAEs). Grade 3 or higher CRS was noted in 13% of patients following the primary analysis and 12% with the update; 28% of patients experienced
neurologic toxicities at the point of the primary analysis, which increased to 31% by the time of the current updated analysis. Grade 5 AEs were also documented in a small proportion of patients. Further, infections were the most common new-onset treatment-emergent SAEs at 6 months, but were resolved by the time of data cut off in August.
Biomarker clues were investigated by the ZUMA-1 researchers who identified several serum biomarkers associated with neurologic events and CRS of grade 3 or higher (including IL-6, IL-10, IL-15, IL-2Rα, and granzyme B). IL-2, granulocyte-macrophage colony-stimulating factor, and ferritin were significantly associated only with neurologic events of grade 3 or higher.
Based on these findings, Neelapu concluded that although a median DOR or OS had not been reached, durable response was observed in both patients who had detectable persistent CAR T cells and those who did not, which he said could be attributed to CD19 loss or immune checkpoint activation, according to some preliminary observations
by the study group.
Become a Member to see the rest of this article and get access to all of our articles and resources. Membership is Free!